Biocon Dreams To Be Among The Top Three Biosimilar Firms As Stelara Rival Gets Japan Approval

The Ustekinumab Biosimilar Is Set For US Launch At The End Of February

 
• By Urtė Fultinavičiūtė

Celebrating its first birthday as a transformed and integrated company, Biocon casts a wider net for its ustekinumab biosimilar.

Silhouette of a person celebrating raising arms on the top stairs with over sunlight
(Shutterstock)

More from Strategy

More from Products